EUVIMEDEUVIMED entdecken
Crossref

Return of gemtuzumab ozogamicin in acute myeloid leukemia-Is it for everyone with CD33 + disease?

Prajwal Boddu, Farhad Ravandi

Advances in Cell and Gene Therapy · 2018

DOI: 10.1002/acg2.21 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Cell and Gene Therapy, 2018. Verfasst von Prajwal Boddu und 1 weiteren Autor:innen. Die Arbeit nennt 67 Literaturangaben. Gefördert von: University of Texas MD Anderson Cancer Center, Leukemia Spore Grant.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • University of Texas MD Anderson Cancer Center
  • Leukemia Spore Grant

Zitieren

APA

Boddu, P., & Ravandi, F. (2018). Return of gemtuzumab ozogamicin in acute myeloid leukemia-Is it for everyone with CD33 + disease?. Advances in Cell and Gene Therapy. https://doi.org/10.1002/acg2.21

Vancouver

Boddu P, Ravandi F. Return of gemtuzumab ozogamicin in acute myeloid leukemia-Is it for everyone with CD33 + disease?. Advances in Cell and Gene Therapy. 2018. doi:10.1002/acg2.21

BibTeX
@article{Boddu2018,
  author = {Boddu, Prajwal and Ravandi, Farhad},
  title = {Return of gemtuzumab ozogamicin in acute myeloid leukemia-Is it for everyone with CD33 + disease?},
  journal = {Advances in Cell and Gene Therapy},
  year = {2018},
  doi = {10.1002/acg2.21}
}
Kostenlos starten →